What are the main alternatives to Cosentyx (secukinumab) for psoriasis?
Cosentyx (secukinumab) targets IL-17A. The closest alternatives are other biologics that work through the IL-17 pathway or switch to different psoriasis mechanisms.
Other IL-17 inhibitors (same pathway as Cosentyx)
Patients and clinicians often consider IL-17 blockers such as:
- Brodalumab (IL-17 receptor A)
- Ixekizumab (IL-17A)
These are commonly used when a patient wants to stay within the IL-17 approach but change dose/response/tolerability.
IL-23 inhibitors (different mechanism)
Another major alternative class for plaque psoriasis is IL-23 inhibition. These can be considered when IL-17 drugs are not a fit.
TNF-alpha inhibitors (older biologic class)
Some people use TNF-alpha inhibitors for moderate-to-severe plaque psoriasis, especially if they have comorbidities where that class is preferred.
What alternatives exist if Cosentyx doesn’t work or stops working?
If Cosentyx is ineffective or loses response over time, options typically fall into two directions:
- Switch within biologics (for example, from IL-17A to another IL-17 blocker, or to an IL-23 inhibitor or TNF inhibitor).
- Consider non-biologic systemic treatments (like methotrexate or other conventional systemic therapies) depending on severity, prior treatments, and clinician preference.
Are there biosimilars for Cosentyx?
Whether biosimilars are available depends on local approval status and the underlying exclusivity/patent situation for secukinumab. You can check current development and exclusivity tracking at DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search “secukinumab” or “Cosentyx”).
How do alternatives compare for psoriatic arthritis?
Cosentyx is also used for psoriatic arthritis, so alternatives depend on whether treatment targets skin disease, joint disease, or both. In practice, clinicians may choose:
- Other IL-17 pathway agents if IL-17 remains attractive for the patient’s pattern of symptoms.
- IL-23 or TNF-alpha–based biologics if a different immune pathway is preferred.
Choice also depends on prior biologics and how active the joints are.
What should patients ask their dermatologist before switching?
Patients usually get clearer answers by asking:
- What’s the treatment goal (skin control, joint control, both)?
- What previous therapies have already been tried, and why did they stop (no response vs side effects)?
- What monitoring is needed with the alternative (labs, infection screening, vaccination timing)?
- How fast the alternative is expected to help and what would count as success.
Sources
No sources were provided in the prompt, and I don’t have access to any external database content beyond what you included. If you share whether you mean plaque psoriasis, psoriatic arthritis, or another Cosentyx indication (and what country you’re in), I can narrow the alternatives to those most relevant.